Bio-Rad Laboratories, Inc. (BIO)

Market Cap	7.59B
Revenue (ttm)	2.55B
Net Income (ttm)	319.20M
Shares Out	27.06M
EPS (ttm)	11.49
PE Ratio	24.39
Forward PE	27.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242,384
Open	284.55
Previous Close	285.90
Day's Range	278.64 - 285.45
52-Week Range	211.43 - 387.99
Beta	0.96
Analysts	Strong Buy
Price Target	333.50 (+18.96%)
Earnings Date	Oct 29, 2025

About BIO

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science e...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1952
• Employees: 7,700
• Stock Exchange: NYSE
• Ticker Symbol: BIO
• Website: https://www.bio-rad.com

Financial Performance

In 2024, Bio-Rad Laboratories's revenue was $2.57 billion, a decrease of -3.92% compared to the previous year's $2.67 billion. Losses were -$1.84 billion, 189.4% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for BIO stock is "Strong Buy." The 12-month stock price target is $333.5, which is an increase of 18.96% from the latest price.

Price Target

$333.5

(18.96% upside)

Analyst Consensus: Strong Buy